Company news
Axsome Therapeutics, Inc. news in 2024
Axsome Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation
December 29, 2024
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024
November 7, 2024
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
October 28, 2024
Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12
October 14, 2024
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
September 3, 2024
Axsome Therapeutics to Participate in Investor Conferences in September
August 26, 2024
Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.
August 20, 2024
Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 4, 2024
Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5
July 10, 2024
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
June 4, 2024
Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
June 3, 2024
Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
June 2, 2024
Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024
May 28, 2024
Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting
May 27, 2024
Axsome Therapeutics to Present at Upcoming Investor Conferences
May 7, 2024
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 5, 2024
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
April 30, 2024
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
April 14, 2024
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
April 9, 2024
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
March 31, 2024
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
March 24, 2024
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
March 24, 2024
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
March 18, 2024
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
March 4, 2024
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
February 26, 2024
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 19, 2024
Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20
January 22, 2024
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
January 3, 2024
Calls in 2024
- Axsome Therapeutics (NASDAQ:AXSM) Q3 2024 Earnings Call
Nov 12, 2024
Transcript - Axsome Therapeutics (NASDAQ:AXSM) Q2 2024 Earnings Call
Aug 5, 2024
Transcript - Axsome Therapeutics (NASDAQ:AXSM) Q1 2024 Earnings Call
May 6, 2024
Transcript - Axsome Therapeutics (NASDAQ:AXSM) Q4 2023 Earnings Call
Jan 4, 2024
Transcript
Decks in 2024
- Technical Presentation (December 2024)
Technical · 31 slides · Dec 30, 2024
- Q3 2024 Earnings Presentation
Earnings · 48 slides · Nov 12, 2024
- Technical Presentation (March 2024)
Technical · 25 slides · Mar 25, 2024
- Investor Presentation (February 2024)
Investor deck · 41 slides · Feb 20, 2024
- Investor Presentation (January 2024)
Investor deck · 41 slides · Jan 8, 2024